drugset / Trial / NCT03849235

A Pathophysiological Study of the Postprandial Human Liver (PLS)

NCT03849235 ↗

Non-randomizedParallel-groupOpen-labelBasic science

Summary

Fatty liver disease is a globally widespread disease. The identification of valid biomarkers and targets for potential treatments requires in-depth knowledge about the pathophysiology of the postprandial liver. The study will consist of seven work packages (WP) including blood tests and liver biopsies taken after fasting or ingestion of a standardized meal in: healthy controls (WP 1), patients with NAFLD (WP 2), and patients with cirrhosis (WP 3) ; before and after a standardised meal in healthy controls (WP 4), and before and after glucagon in healthy controls (WP5), patients with NAFLD (WP6), and patients with T2DM and NAFLD (WP7).

Timeline

Start
2019-03-02
Primary completion
2025-08-21
Completion
2025-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Glucagon bolus Unknown 0.2 mg Intravenous